Epizyme, Inc.
COMBINATION THERAPY FOR TREATING CANCER
Last updated:
Abstract:
The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
Status:
Application
Type:
Utility
Filling date:
16 Jan 2019
Issue date:
30 Jan 2020